NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
相关临床试验
15
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
已完成
14
93.3%
招募中
1
6.7%
暂无批准数据
• NeuroBo Pharmaceuticals has completed the last patient visit in its Phase 2a clinical trial evaluating DA-1241 for metabolic dysfunction-associated steatohepatitis (MASH). • The Phase 2a trial consists of two parts: DA-1241 versus placebo, and DA-1241 in combination with sitagliptin versus placebo. • The primary endpoint is the change from baseline in alanine transaminase (ALT) levels at Week 16, with topline data expected in December 2024. • DA-1241 is a novel GPR119 agonist with potential as a standalone or combination therapy for MASH and type 2 diabetes.
- NeuroBo Pharmaceuticals announced positive top-line data from the Phase 1 clinical trial of DA-1726 for obesity. - The single ascending dose (SAD) study demonstrated favorable safety, tolerability, and dose-linear pharmacokinetics. - DA-1726 is a novel dual agonist of GLP-1 and glucagon receptors, potentially offering improved tolerability over existing GLP-1 agonists. - Top-line data from the multiple ascending dose (MAD) Part 2 study is expected in the first quarter of 2025.
- NeuroBo Pharmaceuticals completed enrollment in the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726 for obesity. - The trial enrolled 45 participants randomized into five cohorts to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726. - DA-1726 is a novel, dual oxyntomodulin analog agonist targeting both GLP-1 and glucagon receptors, showing promise in preclinical studies. - Top-line data from SAD Part 1 is expected in Q3 2024, with MAD Part 2 results anticipated in Q1 2025, and Part 3 dosing planned for Q3 2025.
